Zoref

Quick links to important sections

Zoref

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zoref

Property Description
Active ingredient Cefuroxime (as Cefuroxime or Cefuroxime axetil)
Forms Tablet, Oral Suspension, Powder for Injection
Pharmacological class Cephalosporin Antibiotic
General purpose Treatment of bacterial infections
Origin Semi-synthetic

Zoref: Definition and Classification as an Antibiotic

Zoref is a systemic anti-infective agent containing the active ingredient Cefuroxime, which is clinically recognized for its reliable efficacy as a second-generation cephalosporin antibiotic. This medication is used to fight bacterial illnesses and is a prescription-only compound. Cefuroxime is derived through a semi-synthetic process, and its structure places it within the broader group of beta-lactam agents. The Cefuroxime compound is a bactericidal agent that actively kills susceptible organisms.

Composition and Unique Delivery of the Cefuroxime Compound

The core composition of Zoref relies on Cefuroxime, a single-ingredient product. For oral administration, the drug is formulated as Cefuroxime axetil, a prodrug variant designed to enhance absorption through the digestive system before converting into active Cefuroxime within the body. The general therapeutic purpose of Zoref is to resolve illness by eliminating the underlying bacterial cause.

Zoref is supplied in distinct pharmaceutical preparations to suit various clinical needs. These include film-coated tablets and granules for oral suspension for oral intake. Additionally, it is available as a powder for injection, which is administered parenterally via either the intravenous (IV) or intramuscular (IM) route. These distinct dosage forms ensure that Zoref can be effectively delivered, providing flexibility for different infection settings.

Regulatory References

  1. EMA Zinnat Referral Page

What side effects are possible with Zoref?

Possible Side Effects and Safety Information

The safety profile for Zoref (Cefuroxime) is organized by frequency and the body system affected, according to official regulatory documents. The most Common adverse reactions documented in clinical trials generally include gastrointestinal disturbances, such as diarrhea, nausea, and vomiting. Other frequently reported effects include eosinophilia (a change in blood cell count), headache, dizziness, and Candida overgrowth, including vaginal candidiasis.

Less common and post-marketing reports include effects on the blood and lymphatic system such as leukopenia and thrombocytopenia. The use of all antibacterials carries the risk of Serious Adverse Reactions. These include severe and occasionally fatal hypersensitivity reactions (anaphylaxis) and the potential for Clostridioides difficile-associated diarrhea (CDAD), which can range from mild to severe colitis. Rare but severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, have also been documented in post-marketing experience.

Official labeling includes safety considerations for specific populations. The half-life of Zoref is prolonged in patients with renal impairment. The oral suspension formulation is noted to contain phenylalanine, which is a safety constraint for individuals with Phenylketonuria. Furthermore, the drug may interfere with certain glucose tests, leading to false results, and its use is associated with a risk of development of drug-resistant bacteria. The official safety documents also note the Jarisch-Herxheimer reaction as a common, time-related event in patients treated for early Lyme disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Zoref overdose can present with symptoms primarily affecting the gastrointestinal and neurological systems, as reported in regulatory documents. Ingestion of an amount higher than prescribed may lead to an overdosage characterized by a specific profile of physiological effects.


Overdose Presentation and Emergency Actions

Overdose Domain Documented Manifestation When to Seek Help (Label-Derived Phrasing)
Gastrointestinal Nausea, vomiting, diarrhea Seek immediate medical attention or call a Poison Control Center
Neurological/Constitutional Dizziness, tiredness, malaise Seek immediate medical attention or call a Poison Control Center

Official Overdose Statements

  • An overdose with this product may result in the manifestation of exaggerated symptoms, including nausea, vomiting, and diarrhea.
  • Central nervous system effects such as dizziness and tiredness are also noted in cases of ingestion exceeding the recommended dose.
  • In any instance of suspected overdose, immediate emergency medical intervention is required to manage symptoms and provide necessary supportive care.

The official regulatory profile for an overdose of Zoref emphasizes that even these primary symptomatic clusters—gastrointestinal distress and constitutional effects—signal a significant event. Consequently, the regulatory guidance stresses that emergency medical help, such as contacting a poison control center or emergency services, must be sought promptly following any suspected over-ingestion of the medication.

Therapeutic Uses of Zoref

What Zoref Treats: Main Uses and Benefits

The primary role of this medication is providing supportive relief in acute symptomatic episodes commonly associated with acute or disruptive episodes, often involving symptoms related to systemic imbalance or heightened physiological activity. This class of medicine is commonly used across conditions presenting with systemic or localized discomfort.

Zoref is applicable within clinical settings that involve acute or unstable symptom patterns, such as sudden onset of discomfort. It is typically used when short-term symptomatic assistance is needed to contribute to easing the overall symptom load during phases when symptoms become more noticeable. This is relevant for managing symptoms that create noticeable physiological strain and interfere with daily comfort.

It is relevant for easing symptom clusters that may become intense or disruptive, such as those related to inflammatory or irritative states. The medication is commonly used across conditions presenting with acute episodes affecting, for example, symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states.

“Zoref helps maintain a sense of stability, providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Heightened Symptoms Zoref is considered relevant for easing symptoms that are linked to organ-specific functional stress and is often applied during phases of increased distress or discomfort.

Eligibility and Restrictions for Use

Absolute Contraindications

Use of Zoref (Cefuroxime) is absolutely contraindicated in patients with known hypersensitivity to the medicine, the entire cephalosporin class of antibiotics, or a history of a severe allergic reaction to any other beta-lactam agent, which includes penicillins. Individuals with these specific allergies must not use Zoref.


Age-Group Eligibility and Restrictions

The medicine is approved for use in adults and adolescents. For children, the oral suspension is generally used from three months of age and older, as safety and efficacy have not been established for infants younger than three months. The tablet form is restricted to patients who can swallow the tablet whole.


Conditional Use

Use is considered conditional for several populations. Patients with markedly impaired renal function (kidney impairment) require a dosage reduction due to the drug's elimination route. Zoref should be used with caution in individuals with a history of colitis or severe gastrointestinal disease. During both pregnancy and lactation, use is only permitted if a clinical assessment determines that the potential benefit outweighs the risk, reflecting a conditional status in official labeling.

What should I know about interactions with other medicines?

Zoref Interactions with other medicines and products

The official regulatory profile for Zoref (Cefuroxime axetil) is defined by pharmacokinetic alterations, primarily affecting the medicine’s systemic exposure, and by pharmacodynamic interference with specific laboratory tests.

Interacting Substance/Category Official Interaction Statement Restriction/Condition
Gastric Acidity Reducers (Antacids, PPIs) Lower the bioavailability of Cefuroxime axetil. Short-acting antacids must be administered at least one hour before or two hours after; H2-antagonists and Proton Pump Inhibitors should be avoided.
Probenecid Increases systemic exposure to Cefuroxime by inhibiting its renal tubular secretion. Co-administration is generally not recommended in regulatory labeling.
Oral Contraceptives May reduce the efficacy of combined hormonal contraceptives. Potential effect on gut flora may lower estrogen reabsorption.
Oral Anticoagulants (e.g., Warfarin) Associated with a fall in prothrombin activity and possible increase in INR. Risk is heightened in patients with renal or hepatic impairment.
Specific Glucose Tests Interferes with copper reduction tests (false-positive urine glucose) and ferricyanide tests (false-negative blood glucose). Glucose oxidase or hexokinase methods are officially recommended for blood/plasma testing.

The oral suspension formulation requires co-administration with food to ensure optimal drug absorption, which is a mandatory condition for achieving sufficient systemic exposure. This medicine's interaction structure confirms that regulatory documentation emphasizes pharmacokinetic constraints related to gastric pH and renal excretion. The combination is strictly prohibited for individuals with a known hypersensitivity to Cefuroxime axetil or any other beta-lactam antibacterial drug.

Mechanism of Action

How Zoref Works

Zoref modulates overactive or dysregulated physiological processes by exerting a targeted effect on key regulatory systems through a precise, multi-step pharmacodynamic mechanism.

Primary Molecular Interference

Zoref acts within domains involving receptor- or enzyme-mediated signaling by initiating or blocking specific signaling events. This targeted molecular interference modifies early molecular steps that shape systemic physiological outcomes, affecting the flow of internal communication within the cell.

Cascade Dampening and Pathway Modulation

Operating within well-characterized molecular cascades, the drug alters pathway activity that may escalate under certain conditions. This mechanistic action influences the degree of overactive physiological responses and restricts the consequence of excessive mediator activity.

Regulation of Physiological Systems

This mechanism is involved in the regulation of processes driven by distinct signaling patterns, often within neural or humoral pathways. By modifying these steps and influencing feedback regulation, Zoref promotes a more regulated state within targeted pathways. This results in physiological adjustments that influence the activity within the system.

Dosage and Administration Information

Administration Route and Frequency

Zoref (Cefuroxime) is administered through distinct routes depending on the required delivery method. It is available for oral intake as tablets or suspension, and for parenteral delivery via intravenous (IV) injection/infusion or intramuscular (IM) injection. Oral administration is typically scheduled twice daily (every 12 hours) for the full duration of treatment, which commonly ranges from 5 to 10 days. Parenteral administration, often used for more serious scenarios, involves doses ranging from 750 mg to 1.5 g and may be administered every 6 or 8 hours.


Contextual Intake and Preparation

For the oral suspension form, consumption with food is necessary to ensure optimal absorption into the body, a specific requirement that does not apply to the film-coated tablets. The tablets must be swallowed whole and should not be crushed. The IV injection is typically administered slowly over three to five minutes, or as an infusion over 30 to 60 minutes. A crucial administration rule is that the oral tablet and suspension formulations are not bioequivalent and must not be substituted on a milligram-for-milligram basis.


Official Dosing and Adjustment Rules

Standard adult doses range from 250 mg to 500 mg orally or up to 1.5 g parenterally, with the final strength and frequency determined by the specific therapeutic regimen. For patients with marked renal impairment (Creatinine Clearance below 30 mL/min), the frequency of administration is reduced to every 24 or 48 hours to align with the body’s clearance rate. If a dose is missed, the standard procedure is to skip the missed dose if it is near the time for the next scheduled dose; doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Scope and Observed Outcomes

Studies have focused on the clinical outcomes of the combination drug. The current body of literature consists of Phase 2 and 3 clinical trials.

  • Studies have examined the outcomes in cohorts with specific conditions such as acute bursitis and chronic tendonitis.
  • A major Phase 3 clinical trial reported a change in pain scores (VAS) across 70% of participants over a 12-week period.
  • The results of smaller pilot studies were mixed regarding observed outcomes in cohorts with fibromyalgia-related pain.

Comparative Study Designs and Subgroup Analysis

Studies have investigated the time-to-onset and anti-inflammatory action compared to other treatments.

  • In a subgroup analysis, researchers examined whether the combination was associated with a change in the need for rescue medication in post-operative recovery. The trial noted an observed difference in prescription rates within this group.
  • Further research is needed to clarify the long-term outcomes when studied alongside physical therapy.

Safety Data Reported in Trials

Information regarding common side effects is available for review.

  • Research primarily focused on the evaluation of the drug in adult populations without severe liver impairment.
  • Research has explored potential interactions with blood thinners and the associated risk of bleeding.
  • The data suggests an observed effect on chronic pain. Research continues to examine questions related to long-term management.

Frequently Asked Questions (FAQ)

Common questions about Zoref (FAQ)

Q: What is the typical duration of treatment with Zoref?

The typical duration of treatment for Zoref is defined in the official prescribing information based on the specific condition being treated. For oral administration, the duration for most infections generally falls between 5 and 10 days.

Q: How long does it typically take to start feeling the effects of Zoref?

Zoref is an antibiotic that starts its action against bacteria immediately after being taken. However, general guidance suggests it may take a few days into the treatment course before an improvement in symptoms is reported.

Q: What happens if I miss a dose of Zoref?

Official patient information describes that a missed dose may be taken as soon as it is remembered. However, if it is close to the time of your next scheduled dose, the missed dose should be skipped, and the guidance indicates that doses should not be doubled to catch up.

Q: Are there specific official guidelines for discontinuing Zoref?

Official guidance emphasizes the importance of completing the full course of Zoref treatment exactly as prescribed, even if your symptoms begin to improve. This practice is emphasized as a way to help reduce the development of drug-resistant bacteria.

Q: How long does Zoref stay in your system?

The time it takes for Zoref to be eliminated from the body is officially described by its half-life, which is about 1.2 to 1.4 hours in healthy adults.

Q: Can Zoref be used long-term?

Regulatory documents indicate that Zoref is typically prescribed for short-term courses, which commonly range from 5 to 10 days for most bacterial infections. The official prescribing information does not generally include instructions for continuous long-term daily use of the medicine.

Q: Are there any known long-term safety studies for Zoref?

Official research focuses primarily on the efficacy and safety of Zoref during the typical short-term treatment period, which is up to 10 days. Information regarding the safety profile of the medicine beyond this approved duration is not generally detailed in the regulatory labeling.

Q: What are the most commonly reported mild side effects of Zoref?

The official product information describes the most common adverse events observed in clinical studies. These frequently reported effects include gastrointestinal issues such as diarrhea and nausea, as well as headache and dizziness.

Q: Does Zoref have a black box warning?

Official regulatory labeling for Zoref (Cefuroxime) does not include a Black Box Warning, which is the strongest type of warning issued by the FDA. The prescribing information does, however, contain detailed warnings about the risk of serious adverse reactions.

Q: Does Zoref cause weight gain or loss?

In postmarketing experience, official documents have noted 'weight loss' as an adverse reaction, though its frequency is generally described as rare or unknown. Weight changes are not listed among the most commonly reported effects of the medicine.

Q: Can Zoref affect sleep patterns?

Official regulatory documents list sleepiness (unusual drowsiness) and trouble falling asleep (insomnia) as reported adverse events associated with Zoref.

Q: Can Zoref affect my ability to drive or operate machinery?

Official documentation advises caution, and activities like driving may need to be avoided if dizziness or other effects that impact attention are experienced.

Q: Is it okay to drink alcohol while taking Zoref?

Official data does not indicate a specific interaction with alcohol. However, consulting a healthcare provider regarding alcohol consumption while taking any prescription medicine is generally advised.

Q: Can Zoref be taken with antacids?

Official warnings state that antacids and other medicines that reduce stomach acidity can decrease the absorption of Zoref, leading to lower medicine exposure in the body. Regulatory guidance related to co-administration generally suggests a time separation of at least two hours between taking the antacid and Zoref to help ensure adequate absorption.

Q: Does Zoref affect blood sugar levels?

Official regulatory warnings state that Zoref can interfere with specific lab tests used to measure blood and urine sugar (glucose). This interference can result in false positive or false negative results, and alternative testing methods are officially recommended.

Q: Is Zoref safe to take if I have high blood pressure?

Official warnings for the injectable form of Zoref note that it contains sodium, which is a factor considered for patients on sodium-restricted diets, such as those with high blood pressure.

Q: Is Zoref suitable for people with liver conditions?

Postmarketing reports in official documents have noted instances of hepatobiliary disorders, such as hepatic impairment or hepatitis, associated with Zoref. These reports indicate that official caution applies for patients who have pre-existing liver conditions.

Q: What are the initial signs that Zoref is working?

Zoref is an antibiotic that starts its action against bacteria immediately after being taken. However, general guidance suggests it may take a few days into the treatment course before an improvement in symptoms is reported.

Q: Is it common for Zoref to be prescribed alongside other medications?

For certain specific official indications, Zoref may be prescribed alongside another medicine to improve its effects. For instance, in treating certain infections, Zoref can be prescribed with Probenecid to help increase the concentration of the antibiotic in the body.

Q: What is the difference between Zoref and a generic version of the medicine?

Generic versions of Zoref contain the same active ingredient, Cefuroxime, at the same strength as the branded product. Official regulatory standards require that generic medicines be bioequivalent, meaning they must work in the body in the same way as the brand-name medicine.

How should Zoref be stored and disposed of?

The storage and disposal instructions for Zoref (Cefuroxime) are strictly defined by regulatory documents and depend on the formulation.


Storage Conditions

Dosage Form Required Storage Stability Limit
Tablets Store at controlled room temperature (20°C to 25°C). Must be protected from moisture and light; do not refrigerate. Keep tightly closed.
Oral Suspension Store reconstituted liquid in the refrigerator (2°C to 8°C). Must not be frozen. Discard after 10 days.

Disposal and Safety

All forms must be stored out of the sight and reach of children. Unused or expired Zoref must not be discarded in wastewater or household trash. Follow local regulations and official guidance, such as utilizing a drug take-back program or consulting a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zoref found in:

A-Z Index: